JP2009504135A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009504135A5 JP2009504135A5 JP2008510166A JP2008510166A JP2009504135A5 JP 2009504135 A5 JP2009504135 A5 JP 2009504135A5 JP 2008510166 A JP2008510166 A JP 2008510166A JP 2008510166 A JP2008510166 A JP 2008510166A JP 2009504135 A5 JP2009504135 A5 JP 2009504135A5
- Authority
- JP
- Japan
- Prior art keywords
- therapeutic composition
- mammal
- virus
- protein
- therapeutic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000001225 therapeutic effect Effects 0.000 claims 10
- 241000124008 Mammalia Species 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 102000004169 proteins and genes Human genes 0.000 claims 3
- 108090000623 proteins and genes Proteins 0.000 claims 3
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 2
- 102000003960 Ligases Human genes 0.000 claims 2
- 108090000364 Ligases Proteins 0.000 claims 2
- 241000700605 Viruses Species 0.000 claims 2
- SIIZPVYVXNXXQG-KGXOGWRBSA-N [(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-4-[[(3s,4r)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-3-hydroxyoxolan-2-yl]methyl [(2r,4r,5r)-2-(6-aminopurin-9-yl)-4-hydroxy-5-(phosphonooxymethyl)oxolan-3-yl] hydrogen phosphate Polymers C1=NC2=C(N)N=CN=C2N1[C@@H]1O[C@H](COP(O)(=O)OC2[C@@H](O[C@H](COP(O)(O)=O)[C@H]2O)N2C3=NC=NC(N)=C3N=C2)[C@@H](O)[C@H]1OP(O)(=O)OCC([C@@H](O)[C@H]1O)OC1N1C(N=CN=C2N)=C2N=C1 SIIZPVYVXNXXQG-KGXOGWRBSA-N 0.000 claims 2
- 150000001413 amino acids Chemical group 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 241000710831 Flavivirus Species 0.000 claims 1
- 239000004471 Glycine Substances 0.000 claims 1
- 241000711549 Hepacivirus C Species 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 208000036142 Viral infection Diseases 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 229930182817 methionine Natural products 0.000 claims 1
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 claims 1
- 102000040430 polynucleotide Human genes 0.000 claims 1
- 108091033319 polynucleotide Proteins 0.000 claims 1
- 239000002157 polynucleotide Substances 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 claims 1
- 230000009385 viral infection Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US67768005P | 2005-05-04 | 2005-05-04 | |
| US60/677,680 | 2005-05-04 | ||
| PCT/US2006/016983 WO2006119363A2 (en) | 2005-05-04 | 2006-05-03 | Mutations in oas1 genes |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009504135A JP2009504135A (ja) | 2009-02-05 |
| JP2009504135A5 true JP2009504135A5 (enExample) | 2011-05-12 |
| JP5303728B2 JP5303728B2 (ja) | 2013-10-02 |
Family
ID=37113984
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008510166A Expired - Fee Related JP5303728B2 (ja) | 2005-05-04 | 2006-05-03 | Ｏａｓ１遺伝子内の突然変異 |
Country Status (19)
| Country | Link |
|---|---|
| US (4) | US20060275802A1 (enExample) |
| EP (4) | EP2295552A3 (enExample) |
| JP (1) | JP5303728B2 (enExample) |
| KR (3) | KR20130084323A (enExample) |
| CN (2) | CN101203604A (enExample) |
| AU (1) | AU2006242152B2 (enExample) |
| BR (1) | BRPI0611454A2 (enExample) |
| CA (1) | CA2607575A1 (enExample) |
| HK (1) | HK1209454A1 (enExample) |
| IL (1) | IL187079A (enExample) |
| MX (1) | MX2007013765A (enExample) |
| NO (1) | NO20076126L (enExample) |
| NZ (1) | NZ563785A (enExample) |
| PH (1) | PH12014500829A1 (enExample) |
| RU (2) | RU2465328C2 (enExample) |
| SG (2) | SG175656A1 (enExample) |
| UA (1) | UA95446C2 (enExample) |
| WO (1) | WO2006119363A2 (enExample) |
| ZA (1) | ZA200710521B (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005040428A2 (en) | 2003-10-23 | 2005-05-06 | Illumigen Biosciences, Inc. | Detection of mutations in a gene associated with resistance to viral infection, oas1 |
| UA95446C2 (ru) | 2005-05-04 | 2011-08-10 | Іллюміджен Байосайєнсіз, Інк. | Мутаци в генах oas1 |
| CN103540575A (zh) * | 2006-08-01 | 2014-01-29 | 奇尼塔二有限责任公司 | 医药制造方法 |
| US20120088681A1 (en) | 2010-02-05 | 2012-04-12 | The Translational Genomics Research Institute | Methods and kits used in classifying adrenocortical carcinoma |
| CN103536900B (zh) * | 2012-07-16 | 2017-06-16 | 江苏豪森药业集团有限公司 | 含有促红细胞生成素模拟肽的药物组合物 |
| KR102036532B1 (ko) * | 2015-04-09 | 2019-10-25 | 아이에스피 인베스트먼츠 엘엘씨 | 오염으로부터 피부를 보호하고 피부 재생을 개선하기 위한 화장품 트리트먼트 방법 |
| CN106483282B (zh) * | 2016-09-29 | 2018-08-31 | 北京世纪沃德生物科技有限公司 | 一种抗原稳定剂及其制备方法与应用 |
| US20210315980A1 (en) * | 2018-08-21 | 2021-10-14 | Georgia State University Research Foundation, Inc. | Treatment of flavivirus infections in humans using mus musculus resistant 2'-5' oligoadenylate synthetase 1b |
| WO2021136194A1 (zh) * | 2019-12-30 | 2021-07-08 | 南京金斯瑞生物科技有限公司 | 构建基因突变文库的方法 |
| CN114409744B (zh) * | 2022-03-29 | 2022-10-04 | 深圳吉诺因生物科技有限公司 | Hpv抗原表位及其鉴定方法、应用 |
| WO2023245177A2 (en) * | 2022-06-17 | 2023-12-21 | The University Of Chicago | Targeted nanomedicine for treating lung disorders |
Family Cites Families (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4863873A (en) * | 1980-01-14 | 1989-09-05 | Esa, Inc. | Method for biological testing and/or developing pharmaceuticals for treatment of disorders |
| JPS60222842A (ja) | 1984-04-19 | 1985-11-07 | Fuji Photo Film Co Ltd | ハロゲン化銀写真乳剤およびその製造方法 |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4965188A (en) | 1986-08-22 | 1990-10-23 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme |
| US4800159A (en) | 1986-02-07 | 1989-01-24 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5585481A (en) | 1987-09-21 | 1996-12-17 | Gen-Probe Incorporated | Linking reagents for nucleotide probes |
| US5457183A (en) | 1989-03-06 | 1995-10-10 | Board Of Regents, The University Of Texas System | Hydroxylated texaphyrins |
| CA2044593C (en) | 1989-11-03 | 2004-04-20 | Kenneth L. Brigham | Method of in vivo delivery of functioning foreign genes |
| NZ236819A (en) | 1990-02-03 | 1993-07-27 | Max Planck Gesellschaft | Enzymatic cleavage of fusion proteins; fusion proteins; recombinant dna and pharmaceutical compositions |
| DE4039415A1 (de) * | 1990-02-03 | 1991-08-08 | Boehringer Mannheim Gmbh | Verfahren zur herstellung rekombinanter proteine ohne n-terminalen methioninrest |
| US5279833A (en) | 1990-04-04 | 1994-01-18 | Yale University | Liposomal transfection of nucleic acids into animal cells |
| US5245022A (en) | 1990-08-03 | 1993-09-14 | Sterling Drug, Inc. | Exonuclease resistant terminally substituted oligonucleotides |
| US5404871A (en) | 1991-03-05 | 1995-04-11 | Aradigm | Delivery of aerosol medications for inspiration |
| US6565841B1 (en) | 1991-03-15 | 2003-05-20 | Amgen, Inc. | Pulmonary administration of granulocyte colony stimulating factor |
| NZ244306A (en) | 1991-09-30 | 1995-07-26 | Boehringer Ingelheim Int | Composition for introducing nucleic acid complexes into eucaryotic cells, complex containing nucleic acid and endosomolytic agent, peptide with endosomolytic domain and nucleic acid binding domain and preparation |
| US5858784A (en) | 1991-12-17 | 1999-01-12 | The Regents Of The University Of California | Expression of cloned genes in the lung by aerosol- and liposome-based delivery |
| US5565552A (en) | 1992-01-21 | 1996-10-15 | Pharmacyclics, Inc. | Method of expanded porphyrin-oligonucleotide conjugate synthesis |
| FR2686899B1 (fr) | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant. |
| US5266459A (en) * | 1992-02-24 | 1993-11-30 | The Scripps Research Institute | Gaucher's disease: detection of a new mutation in intron 2 of the glucocerebrosidase gene |
| DE4208916A1 (de) | 1992-03-20 | 1993-09-23 | Akzo Nv | Polyesterfaser und verfahren zu deren herstellung |
| EP0646178A1 (en) | 1992-06-04 | 1995-04-05 | The Regents Of The University Of California | expression cassette with regularoty regions functional in the mammmlian host |
| US5785049A (en) | 1994-09-21 | 1998-07-28 | Inhale Therapeutic Systems | Method and apparatus for dispersion of dry powder medicaments |
| US5574142A (en) | 1992-12-15 | 1996-11-12 | Microprobe Corporation | Peptide linkers for improved oligonucleotide delivery |
| US5915378A (en) | 1993-01-29 | 1999-06-29 | Aradigm Corporation | Creating an aerosolized formulation of insulin |
| US5934272A (en) | 1993-01-29 | 1999-08-10 | Aradigm Corporation | Device and method of creating aerosolized mist of respiratory drug |
| US5558085A (en) | 1993-01-29 | 1996-09-24 | Aradigm Corporation | Intrapulmonary delivery of peptide drugs |
| WO1995022245A1 (en) | 1994-02-18 | 1995-08-24 | Cleveland Clinic Foundation | Antiviral transgenic plants, vectors, cells and methods |
| US5861300A (en) | 1993-03-08 | 1999-01-19 | The Cleveland Clinic Foundation | Antiviral transgenic plants, vectors, cells and methods |
| US5426039A (en) | 1993-09-08 | 1995-06-20 | Bio-Rad Laboratories, Inc. | Direct molecular cloning of primer extended DNA containing an alkane diol |
| US5597709A (en) * | 1994-01-27 | 1997-01-28 | Human Genome Sciences, Inc. | Human growth hormone splice variants hGHV-2(88) and hGHV-3(53) |
| CA2183577C (en) | 1994-03-07 | 2007-10-30 | John S. Patton | Methods and compositions for pulmonary delivery of insulin |
| US5597696A (en) | 1994-07-18 | 1997-01-28 | Becton Dickinson And Company | Covalent cyanine dye oligonucleotide conjugates |
| US5522385A (en) | 1994-09-27 | 1996-06-04 | Aradigm Corporation | Dynamic particle size control for aerosolized drug delivery |
| US5514758A (en) | 1994-09-30 | 1996-05-07 | The Goodyear Tire & Rubber Company | Process for making latex for high performance masking tape |
| US5780014A (en) | 1995-04-14 | 1998-07-14 | Inhale Therapeutic Systems | Method and apparatus for pulmonary administration of dry powder alpha 1-antitrypsin |
| US5480640A (en) | 1995-05-02 | 1996-01-02 | Schering Corporation | Alpha interferon for treating prostate cancer |
| US5654007A (en) | 1995-06-07 | 1997-08-05 | Inhale Therapeutic Systems | Methods and system for processing dispersible fine powders |
| US5840565A (en) * | 1995-08-22 | 1998-11-24 | The Regents Of The University Of California | Methods for enhancing the production of viral vaccines in PKR-deficient cell culture |
| US6077543A (en) | 1996-12-31 | 2000-06-20 | Inhale Therapeutic Systems | Systems and processes for spray drying hydrophobic drugs with hydrophilic excipients |
| US5765887A (en) | 1997-01-07 | 1998-06-16 | P Ii Inc | Apparatus and method for searching pockets and crevices |
| US5993738A (en) | 1997-05-13 | 1999-11-30 | Universal Air Technology | Electrostatic photocatalytic air disinfection |
| US5855564A (en) | 1997-08-20 | 1999-01-05 | Aradigm Corporation | Aerosol extrusion mechanism |
| WO1999013075A2 (en) | 1997-09-08 | 1999-03-18 | Princeton University | Human genes regulated by human cytomegalovirus and interferon |
| FR2770300B1 (fr) | 1997-10-27 | 1999-12-31 | Vincent Patrice Chritin | Dispositif pour la mesure de la vitesse d'un fluide et pour la mesure des flux de particules solides ou liquides dans les fluides ou le vide |
| US6558955B1 (en) * | 1998-03-30 | 2003-05-06 | Esa Inc. | Methodology for predicting and/or diagnosing disease |
| US5958773A (en) | 1998-12-17 | 1999-09-28 | Isis Pharmaceuticals Inc. | Antisense modulation of AKT-1 expression |
| US20010034023A1 (en) * | 1999-04-26 | 2001-10-25 | Stanton Vincent P. | Gene sequence variations with utility in determining the treatment of disease, in genes relating to drug processing |
| US20030165921A1 (en) * | 2000-02-03 | 2003-09-04 | Tang Y. Tom | Novel nucleic acids and polypeptides |
| AU2001245280A1 (en) | 2000-03-07 | 2001-09-17 | Hyseq, Inc. | Novel nucleic acids and polypeptides |
| EP1263956A2 (en) * | 2000-03-09 | 2002-12-11 | Chiron Corporation | Human genes and gene expression products |
| US20020110815A1 (en) | 2000-04-14 | 2002-08-15 | James Lillie | Novel genes, compositions and methods for the identification, assessment, prevention, and therapy of human cancers |
| FR2823224B1 (fr) | 2001-04-04 | 2003-10-31 | Pasteur Institut | Utilisation de genes oas impliques dans la sensibilite/resistance a l'infection par les flaviviridae pour le criblage de molecules antivirales |
| DE10122206A1 (de) | 2001-05-08 | 2002-11-28 | Switch Biotech Ag | Verwendung von Polypeptiden oder diese kodierende NukleInsäuren einer 2'-5'- Oligoadenylate Synthetase und/oder RNAseL zur Diagnose, Prävention oder Behandlung von Hauterkrankungen oder Wundheilung sowie ihre Verwendung zur Identifizierung von pharmakologisch aktiven Substanzen |
| WO2002090552A2 (en) | 2001-05-08 | 2002-11-14 | Switch Biotech Ag | Use of 2'-5'-oligoadenylate synthetase and/or rnasel or nucleic acids encoding them for diagnosis, prophylaxis or treatment of wound healing |
| US6818420B2 (en) * | 2002-02-27 | 2004-11-16 | Biosource International, Inc. | Methods of using FET labeled oligonucleotides that include a 3′-5′ exonuclease resistant quencher domain and compositions for practicing the same |
| GB0208928D0 (en) | 2002-04-19 | 2002-05-29 | Imp College Innovations Ltd | Methods |
| WO2003092618A2 (en) * | 2002-04-30 | 2003-11-13 | University Of South Florida | Materials and methods for prevention and treatment of rna viral diseases |
| WO2004044124A2 (en) * | 2002-05-17 | 2004-05-27 | Baylor College Of Medicine | Identification of oligoadenylate synthetase-like genes |
| AU2003248723A1 (en) | 2002-06-19 | 2004-01-06 | Georgia State University Research Foundation, Inc. | Compositions and methods for viral resistance genes |
| US20050191649A1 (en) | 2003-10-23 | 2005-09-01 | Illumigen Biosciences, Inc. | Detection of mutations in a gene associated with resistance to viral infection, OAS1 |
| WO2005040428A2 (en) | 2003-10-23 | 2005-05-06 | Illumigen Biosciences, Inc. | Detection of mutations in a gene associated with resistance to viral infection, oas1 |
| UA95446C2 (ru) | 2005-05-04 | 2011-08-10 | Іллюміджен Байосайєнсіз, Інк. | Мутаци в генах oas1 |
-
2006
- 2006-03-05 UA UAA200713492A patent/UA95446C2/ru unknown
- 2006-05-03 US US11/416,790 patent/US20060275802A1/en not_active Abandoned
- 2006-05-03 SG SG2011076403A patent/SG175656A1/en unknown
- 2006-05-03 KR KR1020137015261A patent/KR20130084323A/ko not_active Ceased
- 2006-05-03 JP JP2008510166A patent/JP5303728B2/ja not_active Expired - Fee Related
- 2006-05-03 EP EP10183486A patent/EP2295552A3/en not_active Withdrawn
- 2006-05-03 KR KR1020147023680A patent/KR20140109510A/ko not_active Ceased
- 2006-05-03 MX MX2007013765A patent/MX2007013765A/es active IP Right Grant
- 2006-05-03 RU RU2007144986/10A patent/RU2465328C2/ru not_active IP Right Cessation
- 2006-05-03 EP EP20140189399 patent/EP2860246A1/en not_active Withdrawn
- 2006-05-03 CN CNA2006800220895A patent/CN101203604A/zh active Pending
- 2006-05-03 AU AU2006242152A patent/AU2006242152B2/en not_active Ceased
- 2006-05-03 CA CA002607575A patent/CA2607575A1/en active Pending
- 2006-05-03 NZ NZ563785A patent/NZ563785A/xx not_active IP Right Cessation
- 2006-05-03 EP EP10184942.0A patent/EP2314675B1/en not_active Not-in-force
- 2006-05-03 BR BRPI0611454-7A patent/BRPI0611454A2/pt not_active IP Right Cessation
- 2006-05-03 CN CN201310157513.9A patent/CN103642898A/zh active Pending
- 2006-05-03 SG SG10201502945PA patent/SG10201502945PA/en unknown
- 2006-05-03 WO PCT/US2006/016983 patent/WO2006119363A2/en not_active Ceased
- 2006-05-03 KR KR20077028236A patent/KR101476844B1/ko not_active Expired - Fee Related
- 2006-05-03 EP EP06758989A patent/EP1877550A2/en not_active Withdrawn
-
2007
- 2007-01-01 ZA ZA200710521A patent/ZA200710521B/xx unknown
- 2007-11-01 IL IL187079A patent/IL187079A/en not_active IP Right Cessation
- 2007-11-27 NO NO20076126A patent/NO20076126L/no unknown
-
2008
- 2008-10-09 US US12/248,810 patent/US8030046B2/en not_active Expired - Fee Related
-
2011
- 2011-07-11 US US13/180,132 patent/US8951768B2/en not_active Expired - Fee Related
- 2011-10-03 HK HK15110007.3A patent/HK1209454A1/en unknown
-
2012
- 2012-07-30 RU RU2012132651/10A patent/RU2012132651A/ru not_active Application Discontinuation
- 2012-11-14 US US13/676,928 patent/US9163222B2/en not_active Expired - Fee Related
-
2014
- 2014-04-14 PH PH12014500829A patent/PH12014500829A1/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201009135B (en) | Amino acid sequences directed against envelope proteins of a virus and polypeptides comprising the same for the treatment of viral diseases | |
| JP2009504135A5 (enExample) | ||
| JP2011530309A5 (enExample) | ||
| WO2008103380A3 (en) | Hepatitis b virus compositions and methods of use | |
| JP2011528896A5 (enExample) | ||
| EP2460533A3 (en) | Yeast-based therapeutic for chronic hepatitis C infection | |
| IL210455A (en) | A polypeptide for reducing mammalian signaling 13il, and using a polypeptide to produce a drug for up-regulating gene expression 2ra13-il in mammals | |
| FI3778885T3 (fi) | Muokattujen ihmisen arginaasien koostumuksia ja menetelmiä syövän hoitamiseksi | |
| IL183346A0 (en) | Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides | |
| WO2006096459A3 (en) | Infectious, chimeric hepatitis c virus, methods of producing the same and methods of use thereof | |
| TW200745035A (en) | Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors | |
| WO2008106058A3 (en) | Inhibitors of serine proteases | |
| PL2186830T3 (pl) | Interferon alfa 2b zmodyfikowany glikolem polietylenowym, jego wytwarzanie i zastosowanie | |
| WO2009025759A8 (en) | Tight junction proteins associated with infection and entry of hepatitis c virus (hcv), methods and uses thereof | |
| WO2008069917A3 (en) | Novel cyclic peptides | |
| WO2009024327A3 (en) | New proteins for use in human and animal staphylococcus infections | |
| WO2008005880A3 (en) | Antibodies for norovirus | |
| RU2012132651A (ru) | Мутации в генах oas1 | |
| JP2007531741A5 (enExample) | ||
| DE602005020165D1 (de) | Verfahren zur herstellung von l-arginin, l-ornithin oder l-citrullin | |
| RU2008146997A (ru) | Способ блокирования заражения флавивирусами молекулы и применения | |
| NZ599590A (en) | Factor involved in latent infection with herpesvirus, and use thereof | |
| EP2589658A4 (en) | PARTIAL REGION POLYPEPTIDE OF REIC / DKK-3 PROTEIN | |
| WO2007064844A3 (en) | Anti-viral griffithsin compounds, compositions, and methods of use | |
| JP2006158399A5 (ja) | 細胞増殖抑制タンパク質並びにそれを用いる細胞増殖抑制剤、癌診断薬及び癌治療剤 |